The 2024 Seoul National University – Hokkaido University Joint Symposium was held with the theme "Exploring New Frontiers in Convergent Science and Technology." It brought together leading researchers and institutions to discuss cutting-edge advancements and to foster international collaboration. Hosted by the Graduate School of Convergence Science and Technology (GSCST) at Seoul National University, in partnership with Hokkaido University, the symposium featured a variety of talks, poster sessions, and networking opportunities.

CCADD attended the symposium, and more importantly, presented study results highlighting our research projects. As the dean of GSCST, Professor Howard Lee delivered a talk entitled "Application of Artificial Intelligence to Clinical Trials." The presentation emphasized that while AI in clinical trials is still in its infancy, its transformative potential cannot be overlooked. Professor Lee highlighted the importance of understanding the clinical domain to maximize AI’s impact, setting the stage for a future where AI can fundamentally improve trial success rates and the efficiency of drug development. 

CCADD members also delivered poster presentations that showcased the breadth of our research. Jung-Hyun Won explored the feasibility of utilizing single-center real-world data from SNUH’s EMR system, demonstrating its representativeness for cancers such as liver and pancreatic cancer. David Seung U Lee introduced a cost-effective approach to enhance large language models for extracting clinical information from real-world clinical notes, focusing on optimizing prompt configurations and addressing data drift challenges. Yujin Kim presented a novel strategy for extracting chemotherapy-related adverse events in pediatric leukemia patients by combining structured data analysis with minimal manual chart reviews. Lastly, Yunjin Choi conducted an indirect comparative analysis of the efficacy between Tisagenlecleucel, a CAR-T cell therapy, and salvage/reinduction chemotherapy in pediatric relapsed/refractory leukemia, highlighting the complete remission rates achieved by CAR-T therapy. 

This joint symposium provided a valuable opportunity to learn from diverse research fields and exchange insights, fostering mutual growth and collaboration among participants.